first glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy FIRST GLP-1 PILL: The FDA

Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy

Ruth Loos, a genetic epidemiologist at the University of Copenhagen, who was not involved in the study, noted that the extra weight loss, on average, may not seem like a lot, but that for those with two copies of the GLP1R variant, it was more than 10 percent of the total weight loss that people experienced in the study population

Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study

Postpartum use of Shavari Bar improves breast milk output: A double-blind, prospective, randomized, controlled clinical study